This is the authors' abstract. We don't add key points for this paper.
Because catalytically-inactive BTK is insensitive to active-site BTK inhibitors, the mechanism involving the noncatalytic BTK uncovered here may contribute to preexisting reduced sensitivity or even primary resistance of CLL to these drugs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wist et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: